Oxolife Appoints International Fertility Experts to its Scientific Advisory Board

by Oxolife

Oxolife, the specialized biotech focused on enhancing embryo implantation in women undergoing Assisted Reproductive Technology (ART) fertility treatment, today announces it has appointed globally reno...

Read more

Progress in the maturity of the start-ups: the clinical phases

by GENESIS Biomed

The start-ups Oxolife, Peptomyc and aptaTargets, with which GENESIS Biomed collaborates, are advancing in their maturity with the initiation and development of clinical phases and are approaching an e...

Read more

GENESIS Biomed provides support to different projects in the field of in vitro fertilisation

by GENESIS Biomed

It is estimated that infertility affects over 75 million women around the world and over 3 million assisted reproductive techniques are performed each year. In Spain, assisted reproduction treatments ...

Read more

Ensayan un nuevo fármaco para mejorar la fertilidad de las mujeres con ovario poliquístico

by Fundación Andaluza para la Divulgación de la Innovación y el Conocimiento

Oxolife, la biotecnológica enfocada a tratar la infertilidad femenina, y el grupo de Balance Energético, Pubertad y Salud Reproductiva, de la Universidad de Córdoba han establecido una colaboració...

Read more

Covid-19: first-hand experiences from entrepreneurs

by GENESIS Biomed

The SARS-CoV-2 pandemic that is hitting many countries has clearly affected the medical start-up and spin-off ecosystem. After talking to some of the companies we support we have seen that it has not ...

Read more

The biotech company, Oxolife, raises 5 million euros for its Phase II Clinical Trial

by Oxolife

The biotech company Oxolife, created to develop a new treatment to improve the female fertility rate, completed its first funding round by raising 5,000,000 euros in an investment led by Inveready Ass...

Read more

We could hit a new milestone in the treatment of infertility

by GENESIS Biomed

Agnès Arbat and Ignasi Canals lead Oxolife, a startup that is developing OXO-001, a drug with the potential to treat female infertility as it increases the chances of embryo implantation a 65%. Arba...

Read more

Estamos ante lo que puede ser un nuevo hito en el tratamiento de la infertilidad

by GENESIS Biomed

Agnès Arbat y Ignasi Canals lideran Oxo​life, una startup que desarrolla OXO-001, un fármaco con el potencial de tratar la infertilidad femenina al incrementar en un 65% la implantación embrionar...

Read more
Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Photos Stream